Historical salary details - Dr. Arie S. Belldegrun, F.A.C.S.,M.D., Chairman of the Board, Kronos Bio Inc
Dr. Arie S. Belldegrun, F.A.C.S.,M.D. is the Chairman of the Board of Kronos Bio Inc. They also hold 3 other positions in Allogene Therapeutics Inc, UroGen Pharma Ltd and Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A.
Dr. Arie S. Belldegrun, F.A.C.S.,M.D.
Chairman of the Board
-
Gross Remuneration
-
Current Company
Kronos Bio Inc
| YEAR | COMPANY | POSITION | SALARY | INCREMENT |
|---|---|---|---|---|
| 2024 | Kronos Bio Inc | Chairman of the Board | - | - |
| 2024 | Allogene Therapeutics Inc | Executive Chairman of the Board | - | - |
| 2024 | UroGen Pharma Ltd | Chairman of the Board | - | - |
| 2024 | Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A | Independent Director | - | - |
| 2023 | Allogene Therapeutics Inc | Executive Chairman of the Board | 9.4 M | -4.6 % |
| 2023 | Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A | Independent Director | 457.5 K | -18.8 % |
| 2023 | UroGen Pharma Ltd | Chairman of the Board | 342.2 K | 32.4 % |
| 2022 | Allogene Therapeutics Inc | Executive Chairman of the Board | 9.8 M | 44.9 % |
| 2022 | Ginkgo Bioworks Holdings Inc - Warrants (23/02/2026) | Independent Director | 563.5 K | - |
| 2022 | Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A | - | 563.5 K | 3302.2 % |
| 2022 | UroGen Pharma Ltd | Chairman of the Board | 258.5 K | -24.6 % |
| 2022 | Kronos Bio Inc | Chairman of the Board | 158.5 K | -62.2 % |
| 2021 | Allogene Therapeutics Inc | Executive Chairman of the Board | 6.8 M | 30.0 % |
| 2021 | Kronos Bio Inc | Chairman of the Board | 419.0 K | 318.1 % |
| 2021 | UroGen Pharma Ltd | Chairman of the Board | 342.7 K | -16.9 % |
| 2021 | Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A | Independent Director | 16.6 K | - |
| 2020 | Allogene Therapeutics Inc | Executive Chairman of the Board | 5.2 M | -28.8 % |
| 2020 | UroGen Pharma Ltd | Chairman of the Board | 412.5 K | -12.7 % |
| 2020 | Kronos Bio Inc | Chairman of the Board | 100.2 K | - |
| 2020 | Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A | Independent Director | - | - |
| 2019 | Allogene Therapeutics Inc | Executive Chairman of the Board | 7.3 M | -27.2 % |
| 2019 | UroGen Pharma Ltd | Chairman of the Board | 472.7 K | -76.2 % |
| 2019 | Kronos Bio Inc | Chairman of the Board | - | - |
| 2018 | Allogene Therapeutics Inc | Executive Chairman of the Board | 10.0 M | - |
| 2018 | UroGen Pharma Ltd | Chairman of the Board | 2.0 M | - |
| 2017 | Teva- Pharmaceutical Industries Ltd. - ADR | - | 12.1 K | - |
| 2017 | Allogene Therapeutics Inc | Executive Chairman of the Board | - | - |
| 2017 | UroGen Pharma Ltd | Chairman of the Board | - | - |
| 2016 | Teva- Pharmaceutical Industries Ltd. - ADR | Independent Director | - | - |
| 2016 | UroGen Pharma Ltd | Chairman of the Board | - | - |
| 2015 | Teva- Pharmaceutical Industries Ltd. - ADR | Director | - | - |
| 2014 | Teva- Pharmaceutical Industries Ltd. - ADR | Director | - | - |
| 2013 | Capricor Therapeutics Inc | Director | - | - |
| 2013 | Teva- Pharmaceutical Industries Ltd. - ADR | Director | - | - |
| 2012 | Capricor Therapeutics Inc | Director | - | - |
| 2012 | Teva- Pharmaceutical Industries Ltd. - ADR | Director | - | - |
| 2011 | Capricor Therapeutics Inc | Director | - | - |
| 2010 | Capricor Therapeutics Inc | Director | - | - |
| 2009 | Capricor Therapeutics Inc | Director | 136.5 K | - |
| 2008 | Capricor Therapeutics Inc | Director | - | - |